MHRA Amends Guidance for Renewing UK Medicine Marketing Authorisations

We use some essential cookies to make this website work. We’d like to set additional cookies to understand how you use GOV.UK, remember your settings and improve government services. We also use cookies set by other sites to help us deliver content from their services. You have accepted additional cookies. You can change your cookie settings at any time. You have rejected additional cookies. You can change your cookie settings at any time. How to renew marketing authorisations for products granted through different routes and at different times. Added a link to the new electronic Application Forms (eAFs) guidance page. Removed outdated information concerning Brexit including CAPs. Added new information to reflect the Windsor Framework arrangements for medicines. Added information on making applications for variations for category 1 and category 2 products. Updated information regarding CMAs and procedures for products authorised by IRP. Updated guidance on renewal applications to reflect changes to the submission requirements for products within the MR/DCP. ‘The renewals guidance has been updated to provide advice for applicants on the use of the reliance/recognition procedure for both renewals of marketing authorisations and annual renewals of conditional marketing authorisations.’ This guidance provides information on how to renew marketing authorisations ( MA ) for products granted through different routes in the UK following the agreement of the Windsor Framework arrangements for human medicines. It also includes guidance for 5-year renewal of full authorisation and the annual renewal of a conditional marketing authorisation ( CMA ). The Medicines and Healthcare products Regulatory Agency ( MHRA ) acts as the regulator for products placed on the market in Northern Ireland ( NI ). There are some different requirements for products placed on the market in the UK with respect to Great Britain (England, Scotland, Wales) and Northern Ireland. New arrangements for human medicines come into effect from 1 January 2025, reflecting the agreement on human medicines as part of the Windsor Framework. From that date all medicines licensed in the UK will be authorised by the MHRA under the Human Medicines Regulations 2012. Products that fall under the EU’s centralised procedure that were previously automatically granted by the EU in NI (as a centrally authorised product (CAP)) will no longer be authorised in this manner. Instead, these products will be authorised UK-wide under national UK requirements by the MHRA . These products will be known as category 1 products under UK law. Products which do not fall under this category will be known as category 2. An MA will be valid for 5 years from the date of authorisation and market authorisation holders ( MAH ) should continue to submit renewal applications 9 months before expiry, unless the application is being submitted via the International Recognition Procedure ( IRP ). For advice on this procedure please see below, together with further guidance on International Recognition Procedure . The MHRA continues to accept electronic Application Forms (eAFs) for UK medicines licensing applications. As an interim business continuity measure, MHRA is making the current eAF forms available for applicants to download and use. Existing submission routes, validation requirements and assessment processes remain unchanged. Electronic Application Forms (eAF) for UK Medicines Licensing Applications Once an application has been submitted for renewal, the authorisation will remain in force until the MAH is informed of the decision on the application. The authorisation may be renewed for an unlimited period or, where there are pharmacovigilance grounds which require it, for a period of 5 years, after which one further renewal application may be made. The requirements for the content renewal submissions to the MHRA for products authorised in the UK will remain aligned with current EU submission requirements, d